by Scott Harwood | Nov 11, 2025
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). HR-SMM and Darzalex Faspro HR-SMM is an asymptomatic blood and bone...
by Madaline Spencer and Scott Harwood | Oct 27, 2025
The U.S. Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed/refractory multiple myeloma (MM). The indication is for those who have...
by Madaline Spencer and Scott Harwood | Oct 13, 2025
Amit Mehta, MD, Medical Oncologist, discusses data that led to the approval of Wayrilz (rilzabrutinib) for adult patients with immune thrombocytopenia (ITP). ITP is a bleeding disorder characterized by low levels of platelets. It is an autoimmune disorder in...
by Scott Harwood | Mar 4, 2025
Heather Lau, MD, Executive Director of Global Clinical Development at Ultragenyx, discusses positive results regarding gene therapy UX111 for treatment of patients with Sanfilippo syndrome type A (MPS IIIA). MPS IIIA is a severe, progressive disorder that...
by Scott Harwood | Mar 3, 2025
Carlo Antozzi, MD, discusses results from the phase 3 Vivacity-MG3 study of nipocalimab in antibody positive adults with generalized myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles....
